Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial
Primary result · Primary outcome (nonfatal MI, nonfatal stroke or CV death)Result — go to the resultAdjusted hazard ratio 0.94 95% CI 0.77–1.14Authors' conclusion
In high-risk individuals with type 2 diabetes, the use of aspirin for primary prevention was not associated with a decreased risk of incident CVD or all-cause mortality.
Study context
- Population
- ACCORD participants with high-risk T2D without cardiovascular disease (CVD) at baseline; aged 62.8 ± 5.9 years, 43.8% female
- Participants
- 6,330 participants
- Comparison
- Aspirin use vs no aspirin use
- Aspirinn = 3,026
- Primary endpoint
- Composite of:
- Nonfatal MI
- Nonfatal stroke
- CV death
- Follow-up
- Median 4.9 (IQR 4.1-5.7) years
Methodological detailspost hoc analysis, adjusted Cox proportional hazards analysis
- Post hoc analysis
- Adjusted Cox proportional hazards analysis
Primary result
As reported in the abstract
Primary outcome:
- Nonfatal MI
- Nonfatal stroke
- CV death
Adjusted hazard ratio
0.94
95% CI 0.77–1.14
Events by treatment group
Aspirinvs No aspirin
aHR 0.94 (95% CI 0.77–1.14)
Further findings
| Outcome | Aspirin | No aspirin | aHR (95% CI) | |
|---|---|---|---|---|
| All-cause mortality · median 4.9 years | 4.8% | 4.5% | 1.08 (0.85–1.36) | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial. Diabetes Obes Metab. Published 10 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →